British Journal of Dermatology

Article	Citations
Integrating artificial intelligence into skin cancer pathways: the opportunities and obstacles	302
Greater understanding about differences in the long-term course of eczema and their risk factors in children	222
Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights	178
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin	102
561 - Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial	97
Higher proportion of cellulitis in severe lymphoedema	89
一项在一家大型教学医院进行的 5 年皮肤附属器肿瘤研究, 对关联基因诊断提供了启示	83
对化疗所致脱发的更深入了解	80
空气污染会导致皮肤颜色变深	76
P100: Efficacy of current treatments under study in patients with alopecia areata	75
Recognizing psoriasis in children and adolescents: the DIPSOC study	75
BH13: Scarring alopecia affecting a congenital melanocytic naevus in a patient with frontal fibrosing alopecia	74
CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease	71
P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future	71
P57: New order: redesigning referral pathways to improve access for patients from dermatology outpatient waiting lists	70
开展健康宣传活动，禁售日光浴床，以减少皮肤癌: 合理利用医疗预算	69
BH09: Frontal fibrosing alopecia in men: is it any different?	64
Issue Information	64
H10: A Sweet diagnosis to make: the history of Robert Douglas Sweet and acute febrile neutrophilic dermatosis	64
P52: Opportunities for implementing a patient‐initiated follow‐up pathway in patients with psoriasis completing narrowband ultraviolet B phototherapy	64
News and Notices	61
Possible new oral treatment for hidradenitis suppurativa	60
DP27: Maculopapular cutaneous mastocytosis mimicking seborrhoeic folliculitis	58
P53: Office 365: Microsoft Lists as a tool for a secure online second‐line/systemic drug database	57
皮肤红斑狼疮治疗指南	56

DP12: An 11‐year mystery	55
P91: Cutaneous adverse events of immune check point inhibitors nivolumab, pembrolizumab and atezolizumab: a multicentric study	54
Editor's Choice – John Ingram – Sep 2023	54
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?	53
银屑病皮肤细胞中的小分子 RNA 促进炎症发生	52
Correction	52
Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review	51
O22 Unravelling the pathophysiology of KLICK syndrome to identify therapeutically targetable pathways	51
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis	50
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing	48
Development of a shared decision-making tool in vitiligo: an international study	48
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study	47
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with ‘skyline’ basal cell layer (PENS)	47
Atypical melanocytes of an atypical Spitz tumour observed with optical super-high magnification dermoscopy	46
Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma	45
Seeking new topical therapies in psoriasis	43
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme	42
How to score the impact of treatment on cutaneous neurofibromas in clinical trials	42
O11 The human discs large protein (Dlg1) controls connexin 43 (Cx43) plasma membrane localization and gap junctional communication in keratinocytes	41
Delusional infestation – do not be scared!	41
Interactive effect of genetic and environmental risk factors on psoriasis: current evidence and future directives	41
O06 Exploring host–microbiome–immune interactions using singular and multispecies inoculations in optimized 3D skin models	41
Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser	41
Corrigendum	40
BT25: Dermatology and the metaverse: what’s on the horizon?	40
Editor's Choice – John Ingram – December 2023	39
GD07: The use of the Dermatology Life Quality Index suite of patient‐reported outcome measures in neglected tropical diseases of the skin: a systematic review	39
Risankizumab versus apremilast in the era of skin clearance	39
‘Substantial clinical benefit’ and ‘substantial clinical worsening’ cutoff of Vitiligo Impact Scale (VIS)-22 change scores	39
A guide to using the core outcome set for eczema	39
H20 Sarcoptes scabiei: to solve the current crisis, hunt for clues in our past	39
H19 Not only a finder of ‘solutions’: Max Jessner, Holocaust survivor and discoverer of Jessner–Kanof lymphocytic infiltrate	38
BH13 Current wig prescribing practices and financial evaluation in a National Health Service foundation trust: lessons learnt and future challenges	38
H06 The changing face of skin disease in warfare: from World War I to modern times	37
Poster presentationsPA10 Hidradenitis suppurativa and trisomy 21: a case series	36
P068 A history of mycosis fungoides: from Alibert to mogamulizumab	36
Poster presentationsBT15 Ethical implications of artificial intelligence in dermatology: use-case analysis of skin cancer diagnostic smartphone apps	36
DS23 Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma	36
DS17 Two cases of traumatic pseudoaneurysm of the superficial temporal artery	36
DS24 Is surgery the best management for keratoacanthoma centrifugum marginatum?	36
SG08 The phenotypic spectrum of MBTPS2 mutations: two illustrative cases	36
P093 Bespoke omalizumab prescribing in chronic spontaneous urticaria	35
O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR),	35
PA12 Fats and figures: how abnormal lipids unravel the truth	34
BH09 Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia	34
519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months	34
The future of patient-reported outcome measurement in hyperhidrosis lies in thoughtful, evidence-based implementation	33
UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt	33
Missing melanomas in England during the COVID-19 pandemic: 2485 fewer melanoma diagnoses in 2020 than in 2019	33
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study	33

Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department	32
DP10: A case of reactive angioendotheliomatosis with resolution following improved glycaemic control	32
Expanding the SLURP1 disease spectrum: from Mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma	32
Eligibility criteria for programmed death receptor 1 inhibitors vs. real‐world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck	32
Clinical practices and educational interests of dermatologists in Caribbean countries	32
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation*	31
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa	31
Prurigo nodularis: disease burden, clinical features and approach to management	31
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study	31
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa	31
514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age	30
Living with vulval lichen sclerosus: a qualitative interview study	30
Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin β4 subunit	30
Mainstreaming genetic testing in dermatology in the UK	30
Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma	30
WNT10A , dermatology and dentistry	29
COVID-19 vaccines and skin manifestations	29
Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey	29
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey	29
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study	29
Sexual and gender minority inclusivity in hidradenitis suppurativa patient-reported outcomes	29
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study	28
Neutrophil infiltration in allergic contact dermatitis to nickel	28
Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern	28
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials	28
How do dermatologists’ personal models inform a patient‐centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast)*	27
CD03 Contact sensitization to shellac: a possible marker of fragrance allergy	27
Burden of atopic dermatitis in paediatric patients: an international cross-sectional study	27
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry	27
Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded c	27
CPC02 Delayed widespread lichenoid drug reaction with radioisotopic response in a patient treated with nivolumab	26
P74 Guselkumab clinical super-response is associated with faster normalization of blood and skin pathology: data from the Phase 3b GUIDE trial	26
Newborn genome screening (the Generation Study): the advent of presymptomatic diagnosis for genodermatoses	26
P068 Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial	26
730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity	26
PA24 Abnormal interferon signature in a patient with chilblain lupus	25
BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report	25
603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial	25
SG02 Transdermal testosterone improves lower-extremity ulceration in a young man with newly diagnosed Klinefelter syndrome (47 XXY)	25
677 - Establishing a patient-centered definition of atopic dermatitis flare: insights from a modified eDelphi study	25
P67 Overall lifetime risk for alopecia areata is 2.1% and is higher in women, non-White ethnic groups and the most deprived: a UK population-based cohort study	25
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial	25
Body-site specific associations between human skin microbiome composition and psychological wellbeing	25
335 Improvement in sleep quality, anxiety and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment	24
P50 Exploring unmet needs and attitudes to skin self-examination in melanoma survivors: EUNASS study	24
BH18 A rare case of nail sarcoidosis presenting as an ulcerated nail tumour in a Afro-Caribbean patient	24
010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)	24
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging	24
P13 A rare case of Sjögren syndrome in a White woman with Kikuchi–Fujimoto disease	24
DP22 Cutaneous lymphoid hyperplasia: clinicopathological correlation and a therapeutic option	23
SG10 (P058) The epidemiology of epidermolysis bullosa in England, 1997–2024: a retrospective national cohort study	23
PA37 A retrospective review of the impact of virtual reality headsets in paediatric skin surgery	23
BI26 Treatment-induced scleroderma in a patient with metastatic melanoma	22
705 - Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment	22
691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment	22
643 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of short-term (week 8-20) data from a real-world multicenter retrospective review	22
DP21 Thymoma and the skin: manifestations of multiorgan autoimmunity	22
P19 The association between psoriatic disease severity and adherence to the Mediterranean diet: a systematic review of observational studies	22
A current need for the use of improved and standardized outcome measures by clinical studies of pemphigus	22
Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies	22
673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials	22
Pathways to progress: DUSP1-associated palmoplantar keratoderma in the era of precision dermatology	22
P79 A multidisciplinary expert consensus on the assessment of and support for mental health in children and young people living with skin conditions	21
BI08 Defining the burden of mucocutaneous disease in organ transplant recipients living with HIV: the Mucocutaneous disorders in Organ Transplant recipients living with HIV study	21
P099 Spesolimab use in effective treatment of generalized pustular psoriasis: a case report	21
641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis	21
BH10 Nailing the diagnosis	21
H15 A treatment for leprosy developed on the edge of Europe: Vincent Barry (1908–1975)	21
Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma underdiagnosis and delayed care?	20
我们如何评估前额纤维化性脱发的严重程度和治疗?	20
005 Association between prescription drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a UK population-based study	20
P020 A rare phenomenon in a rare disease: reverse Koebner phenomenon in cutaneous Rosai–Dorfman disease	20
Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention	20
便于充分了解炎症后色素沉着的模型	20
Methotrexate and ciclosporin improve skin biomarkers in paediatric atopic dermatitis: results from the TREatment of severe Atopic eczema Trial	20
BT12 A comparison of outcomes and cost-effectiveness in a teledermatology vs. a standard face-to-face 2-week wait UK model	20
The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa	20
BT06 (P163) Implementation of a novel direct-to-patient inflammatory teledermatology service	20
H17 Traditional medicine: a warts-and-all tale	20
O02 Skin cancer service disparities across England: what data can tell us about skin cancer diagnosis, referral pathways and treatment received in different NHS trusts	20

Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis	19
H12: Campbell De Morgan: doctor, scientist, polymath	19
PA02 (P28): Prediction of FLG genotype using human and computer‐aided phenotype extraction with random forest machine learning	19
Review of different staging systems for cutaneous squamous cell carcinoma	19
P40: Histopathological features of orofacial granulomatosis with and without underlying gut Crohn disease	19
阳光与新冠肺炎死亡风险较低有关, 但并非因为维生素 D	19
DS24: Clinical outcomes of cutaneous squamous cell carcinomas treated with Mohs micrographic surgery	19
Editor’s Choice	19
P24: Benzalkonium chloride: a potential emerging allergen in the era of the COVID‐19 pandemic	19
BG12: Cicatricial junctional epidermolysis bullosa: a forgotten subtype	19
BG02 (P35): Alterations of forces applied under the feet in patients with epidermolysis bullosa simplex during gait	19
Adcitmer ® 是 Merkel 细胞癌的潜在治疗方法	19
CD03: Practical use of a limonene and linalool series	18
Patient experiences of living with vulval lichen sclerosus	18
Insights into the biological differences in hair follicles of men with androgenetic alopecia	18
Hidradenitis suppurativa: BJD state-of-the-art review series	18
O01 Inborn errors of metabolism - Solving the puzzle of prolidase deficiency	18
P34: Exploring anaemia in hidradenitis suppurativa: a comparative study and proposal of a clinical pathway	18
P55: Post‐COVID analysis of 2‐week wait face‐to‐face activity and the potential for a teledermatology service	18
体重在 90 公斤或以上的银屑病患者获益于更为频繁的苏金单抗给药	18
Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults	18
Lived experiences of patients with hidradenitis suppurativa-related pain	18
P33 Investigating the utility and exploring biological targets of micro-wound healing compounds in 2D and 3D skin models	18
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa	18
转移性黑色素瘤免疫治疗后患者恢复生活的经验	18
Varied skin reactions after COVID-19 vaccination	18
Correction to: Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply	18
Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease	18
PS02 (P16): Gender and sexual identity: unmet dermatological needs of LGBTQ + individuals and how dermatologists can provide better care: a qualitative analysis of a	17
Genetic basis of a novel rare dominant form of palmoplantar keratoderma	17
Correction to: Microbiome characterization of skin biopsies in Spanish patients with hidradenitis suppurativa shows a decrease in D1 and H1 lineages of Cutibacterium acnes	17
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight	17
P17 Pseudomonas infection causing acute painful flexural exacerbation in a child with IFAP syndrome	17
Tinea capitis in China	17
Parent and child experiences of skin conditions and views on mindfulness-based support	17
Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure	17
Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus	17
P05 Pre-visit online paediatric atopic dermatitis questionnaire – a feasibility study	17
A review of genetic hair disorders	17
A global study of 17 009 women reveals significant skin condition changes associated with irregular menstrual cycles	17
Integrative serum proteomics analysis reveals distinct immune and cardiovascular profile dysregulation in erythrodermic psoriasis	17
A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin	17
P100 Critically appraised topic: is dupilumab a cause or a treatment for alopecia areata? A case series and literature review to guide discussions in clinical practice	16
PS06 Mindfulness-based stress reduction alleviates flushing and negative emotions in rosacea: an exploratory study	16
On the potential beneficial effects of indoor tanning	16
Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumour response to a programmed death-1 inhibitor	16
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries	16
PD15 Ultraviolet overexposure in solar urticaria: beyond the rash	16
P088 Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOST	16
Semi-virtual patch testing: the future?	16
Editor's Choice – John Ingram – March 2024	16
DS05 Overtreatment of skin cancer: how can we ensure those treated for basal cell carcinoma receive more benefit than harm?	16
Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib	16
Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma	16
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab	15
Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study	15
Head lice: evidence that resistance to physically acting treatments is developing	15
The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study	15
Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study	15
What do Hyperhidrosis Quality of Life Index (HidroQoL©) scores mean? Transferring science into practice by establishing a score banding system	15
Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum)	15
Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic	15
Promising results for treatment of severe chronic hand eczema with dupilumab	15
Analysis of laser-generated plume concentration during in vivo laser hair reduction procedures in a tertiary referral laser dermatology unit	15
Getting evidence into practice: C3 will see it through	15
Infectious disease among adults with allergic contact dermatitis: a propensity score-matched case–control study	15
More than skin deep: a survey of real-life experiences of acne vulgaris	15
Trends in antibiotic prescriptions for hidradenitis suppurativa from 2015 to 2021	15
DS03: A scoping review of commercially available artificial intelligence‐based technologies for diagnosis or risk assessment of skin cancer	15
P33 Skinvaders: gamification of the skin barrier to engage school-age children in the biology of the skin	14
O05 Single-cell transcriptomic signature of paradoxical eczema in patients with psoriasis treated with biologics	14
Discovering skin-rejuvenating matrikines: a new frontier in basic and applied dermatology	14
‘Quantity does not make quality’: when is there a case for repeating a network meta‐analysis?	14
Atopic dermatitis, hypertension and cardiovascular disease	14
Geospatial analyses demonstrate variation of cutaneous T-cell lymphomas across Australia, providing insights into possible causes	14
P37 Drug repurposing for treatment of recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma	14
Erratum	14
A study looking at a possible new drug, HB0017, for the treatment of psoriasis	14
533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure	14
The importance of accurate epidemiological data of epidermolysis bullosa	14
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials	14
P059 Cutaneous sarcomas: a 5-year review of treatment outcomes and literature	14
SG06 (P013) Eruptive seborrhoeic keratoses in late-onset constitutional mismatch repair deficiency	14
BI20 A fatal case of disseminated cutaneous Mycobacterium chelonae infection in an immunocompromised patient	14
Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study	14
Younger facial looks are associate with a lower likelihood of several age-related morbidities in the middle-aged to elderly	14
Haematohidrosis	14
Focusing on antigen-specific T cells	14
DS21 Patients’ experience with one-stop skin cancer clinics	13
FC16 Blood mass cytometry reveals Type 1 cytokine expression in blood of patients with paradoxical eczema secondary to biologics for psoriasis	13
DP02 (P30) Declining staff numbers and increasing workload: is there a solution?	13
Atopic dermatitis: filaggrin and skin barrier dysfunction	13
FC26 The MEditerranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis (METRED-P) study: an interim analysis of the first UK-based diet intervention trial	13
P111 An AI-assisted similarity search engine for enhanced psoriasis case identification and patient engagement	13
P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature	13